La NMPA de China aprueba las cápsulas de hidrocloruro de Iptacopan

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#Iptacopan #IptacopanHidrocloruro #Feihada #HPN #HemoglobinuriaParoxísticaNocturna
#NMPA #AprobaciónDeMedicamentos #InnovaciónFarmacéutica

#Iptacopan in Patients With #IgA Nephropathy From East #Asia

#VisualAbstract by Kajaree

www.kireports.org/article/S2468-0249(25)00...

FABHALTA Revolutionizes Complement Inhibitor Market with Oral Administration and Efficacy FABHALTA, an oral complement factor B inhibitor, promises to transform treatments for PNH and IgAN, addressing critical medical needs.

FABHALTA Revolutionizes Complement Inhibitor Market with Oral Administration and Efficacy #United_States #Las_Vegas #Novartis #Fabhalta #iptacopan

perfect timing for the video to go live

youtu.be/Fo6J__RgWA0

#NephGR #C3GN since #iptacopan just got FDA approval for C3GN www.novartis.com/news/media-r...

#NephSky

Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis Novartis’ kidney disease troika keeps marching forward. | Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts spotted several shor...

What a great time to be in the nephrology space
C3GN now has a therapy
👏🏻 👏🏻 👏🏻
Hi #Iptacopan #Fabhalta

www.fiercepharma.com/pharma/novar...

🎉Definitely a hooray dance for #C3G
💊What is an oral agent inhibiting the alternative complement pathway.. selectively targeting the underlying cause of C3G? #iptacopan
💪🏻 APPEAR-C3G - a pivotal phase 3 study

x.com/anuja_java/sta…

🎉Definitely a hooray dance for #C3G
💊What is an oral agent inhibiting the alternative complement pathway.. selectively targeting the underlying cause of C3G? #iptacopan
💪🏻 APPEAR-C3G - a pivotal phase 3 study

x.com/anuja_java/sta…

🌟Beyond Testing—IgAN Trials Unveiled!-Must Read🌟

From #Sparsentan to #Iptacopan, innovative non-immunomodulatory & immunomodulatory therapies are transforming IgAN care!🎯

🔬 Excellent Trial insights by @Melgreux
📖 via @KidneyKolumns Jan25

#Nephrology #IgAN #ClinicalTrials